HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis PDF Print E-mail
Sunday, 01 July 2012 22:09
Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for patients with poor-prognosis, early diffuse cutaneous systemic sclerosis.

The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial enrolled more than 150 patients between 2001 and 2009, and randomised participants to HSCT or IV pulse cyclophosphamide treatment. As of 1 May 2012, significantly more deaths had occurred in the conventional treatment group. Half of the deaths in the HSCT group occurred early and were deemed treatment-related, according to an independent data monitoring committee. In the conventional treatment group in contrast, none of the deaths were deemed to be treatment-related, but more deaths occurred later and most were related to progressive disease.

Speaking on behalf of European Bone Marrow Transplantation (EBMT) EULAR Scleroderma Study Group, Prof Jaap van Laar from Newcastle University, Prof Dominique Farge from Assistance Publique Hôpitaux de Paris and Prof Alan Tyndall from Basel University, explained that initial results from the trial have been very encouraging and help to identify patients who benefit from stem cell transplantation. They added that systemic sclerosis can lead to heart, lung or kidney failure and premature death, especially in patients who have the diffuse cutaneous form of the condition, where skin thickening is more generalised and involvement of vital organs more common. The ASTIS study shows that such patients may benefit from early intensive immunosuppressive treatment, they said.

The ASTIS trial was a unique collaborative project of 27 multidisciplinary teams from 10 countries conducted under the auspices of two leading organisations in the respective fields – EBMT and EULAR. The primary endpoint of the trial was event-free survival, defined as survival until death or development of major organ failure.

Systemic sclerosis is estimated to occur in 2.3 to 10 per million population. Systemic sclerosis is therefore a rare but severe autoimmune systemic connective tissue disease. Increased fibroblast activity results in abnormal growth of connective tissue which causes vascular damage and fibrosis of the skin, GI tract and other internal organs. Characteristics of systemic sclerosis include vasomotor disturbances and fibrosis with subsequent atrophy of the skin, subcutaneous tissue, muscle and internal organs, along with immunologic disturbances. Diffuse cutaneous systemic sclerosis cases make up 30 per cent of all systemic sclerosis cases and involve the upper arms, thighs and trunk. Lung fibrosis and pulmonary hypertension are important causes of mortality in these patients and there is no curative treatment available so far.

Source: Medical Independent (2012), "HSCT benefits in early diffuse cutaneous systemic sclerosis"; Original article can be found here.

 
More articles :

» Predictors Of Interstitial Lung Disease In Early Systemic Sclerosis

Introduction: The objective of the present study was to examine the association of baseline demographic andclinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as apercentage of the predicted...

» Platelet Gel In The Treatment Of Severe Scleroderma Skin Ulcers

Dilia Giuggioli, Michele Colaci, Andreina Manfredi, Mariateresa Mariano and Clodoveo FerriSystemic sclerosis (SSc) is characterized by microvascular damage and fibrosis of the skin and internal organs. Non-healing skin ulcers, mainly non-venous leg...

» Caribbean Autoimmune Diseases 2011 Summit Highlights

On Sunday October 2nd 2011, the Caribbean Investor Network hosted its Caribbean Autoimmune Diseases Summit at the Ballroom of the Hilton Hotel and Conference Centre.The Summit delivered an array of excellent presentations ranging from the common...

» Simple Predictor In Scleroderma Related Interstitial Lung Disease

Patients at high risk of deterioration or death from Systemic Sclerosis-related interstitial lung disease can be readily spotted using CT scans, suggest Melbourne researchers.Patients classified as having “extensive” (> 20%) lung disease as...

» Long-Term Outcomes of Scleroderma Renal Crisis

In a previous study. researchers sought to describe the medical history of a group of patients with Scleroderma Renal Crisis who had been treated with ACE inhibitors. The following is essentially a summary of that study, which was conducted by...

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...